Header Logo

Connection

JOHN KIRKWOOD to Killer Cells, Natural

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Killer Cells, Natural.
JOHN KIRKWOOD
Connection Strength
0.764
Killer Cells, Natural
  1. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020 10 15; 26(20):5520-5533.
    View in: PubMed
    Score: 0.145
  2. CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a. Front Immunol. 2019; 10:14.
    View in: PubMed
    Score: 0.132
  3. Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group. J Immunother. 1997 Mar; 20(2):146-57.
    View in: PubMed
    Score: 0.115
  4. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011 Apr; 34(3):270-8.
    View in: PubMed
    Score: 0.076
  5. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med. 1990 Jan-Feb; 52(1):73-85.
    View in: PubMed
    Score: 0.070
  6. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.042
  7. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
    View in: PubMed
    Score: 0.036
  8. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020 01 09; 10(1):92.
    View in: PubMed
    Score: 0.035
  9. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992 Feb 15; 52(4):851-6.
    View in: PubMed
    Score: 0.020
  10. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol. 1990 Jun; 8(6):1070-82.
    View in: PubMed
    Score: 0.018
  11. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model. Nat Immun Cell Growth Regul. 1990; 9(5):313-24.
    View in: PubMed
    Score: 0.018
  12. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol. 1986 Sep; 13(3 Suppl 2):48-56.
    View in: PubMed
    Score: 0.014
  13. Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
    View in: PubMed
    Score: 0.012
  14. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon (IFN-alpha) in phase I-II trials. J Biol Response Mod. 1983; 2(6):528-39.
    View in: PubMed
    Score: 0.011
  15. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod. 1983; 2(6):540-7.
    View in: PubMed
    Score: 0.011
  16. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther. 2000 Dec; 6(4):171-6.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.